GYRE THERAPEUTICS
Live / Applied — Non-final action mailed (as of 19 Nov 2025)
What this means for you
Not registered yet, but its 23 Jun 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99248258
- Mark type
- Design + words
- Filed
- 23 Jun 2025
- Attorney of record
- Khanh T. Glatzel
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of chronic obstructive pulmonary disease, pulmonary arterial hypertension, acute liver failure, acute-on-chronic liver failure, liver fibrosis, metabolic dysfunction associated fatty liver disease, nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, lung fibrosis, organ fibrosis, and inflammatory diseases
- Class 042 — Scientific and technological services: Conducting early evaluations in the field of new pharmaceuticals; Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Testing of pharmaceuticals
Owner
- Gyre Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 13 Feb 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 13 Feb 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 19 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Nov 2025 — NON-FINAL ACTION E-MAILED
- 19 Nov 2025 — NON-FINAL ACTION WRITTEN
- 12 Nov 2025 — ASSIGNED TO EXAMINER
- 30 Oct 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 30 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 23 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 23 Jun 2025 — NEW APPLICATION ENTERED